#methodological rigourUnresolved heterogeneity complicates the certainty rating
The primary RCT urinary-iodine analysis has I² = 81%, yet its moderate-certainty rating is downgraded only for risk of bias. Post-hoc subgroup analyses do not fully explain the variability.
↳ Figure 6; Summary of findings, footnote 10; Discussion, Summary of main results
#contributionClinical and safety evidence remains sparse
The main positive result concerns urinary iodine rather than prevention of clinically important disorders. Goitre and growth evidence is very uncertain, and adverse-event evidence comes from one small crossover trial.
↳ Abstract, Main results; Summary of findings
#reportingRobustness wording obscures changing effect estimates
Sensitivity analyses are described as not changing the effect, although the RCT estimate moves from SMD 0.59 to 0.73 and the non-RCT estimate from 0.25 to 0.00. The broad statistical conclusions persist, but the wording understates numerical variation.
↳ Abstract, Main results; Results, Sensitivity analysis; Analyses 3.1 and 3.2